produits : BT-001

 

BT-001

BT-001 is a multifunctional oncolytic virus from Invir.IO® platform.

Two specific “weapons” have been integrated into the vaccinia viral DNA: an anti-CTLA4 antibody , which was developed by BioInvent, and the cytokine GM-CSF, which triggers the body’s immune response.

Selectively destroying cancer cells

 
Discover how BT-001 works
* requires analytics cookies

Derived from the Invir.IO® platform, our oncolytic viruses infect, specifically multiply and induce tumor cell lysis (or oncolysis).

 

These viruses also integrate anti-cancer weapons into their genome, enabling them to modulate the tumor microenvironment.

 

These different mechanisms lead to the destruction of tumor cells and the activation of the immune system, while preserving the patient’s own healthy cells.

BT-001 treatment turned “cold” tumors to “hot”

 

Preliminary data showed that BT-001 induces positive local, abscopal and sustained antitumoral activity in advanced refractory tumors.

 

BT-001 replicates in the tumor where the payloads are expressed with undetectable systemic exposure. BT-001 alone or in combination with pembrolizumab was well tolerated and showed first signs of efficacy with clinical responses in 2 of 6 patients who failed previous treatments, when given in combination with pembrolizumab.

 

These immune-mediated tumor shrinkages are consistent with the mechanistic hypothesis that BT-001, in combination with pembrolizumab, turns “cold” tumors into immunologically active ones.

 

Collaboration agreements

Transgene and BioInvent have entered into a clinical trial collaboration and supply agreement with MSD, a tradename of Merck & Co., Inc., Rahway, NJ., USA, to evaluate the combination of the oncolytic virus BT-001 in combination with MSD’s anti-PD-1 checkpoint therapy KEYTRUDA® (pembrolizumab) in a Phase I/IIa clinical trial for the treatment of patients with solid tumors.

Additional ressources

 

Latest press releases

Our innovative multifunctional oncolytic viruses are able to modulate the tumor micro-environment to better attack cancer